In ovarian carcinomas, an alpha1-antiagonist, Nafttopidil, has shown greater efficacy in overcoming resistance to MEK inhibitors via the activation of the JNK signaling pathway and stimulation of BH3-only protein expression [97]. Here, MAPK8 is linked to ovarian carcinoma.